Last reviewed · How we verify
TAB014 Monoclonal Antibody Injection
TAB014 is a monoclonal antibody that targets an unspecified molecular target to treat various conditions.
TAB014 is a monoclonal antibody that targets an unspecified molecular target to treat various conditions. Used for Unspecified indication.
At a glance
| Generic name | TAB014 Monoclonal Antibody Injection |
|---|---|
| Also known as | TAB014 |
| Sponsor | BioDlink Biopharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
TAB014 is a monoclonal antibody designed to bind to a specific protein or receptor, thereby modulating its activity and exerting its therapeutic effects.
Approved indications
- Unspecified indication
Common side effects
- Unspecified adverse event
Key clinical trials
- TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration (PHASE3)
- TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: